1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Aileron, Talaris, Frequency And The Search For Strategic Alternatives

Job Cuts Continue As Programs Fail, Cash Dwindles

 
• By Mandy Jackson

Public Company Edition: Aileron, Talaris and Frequency said they will reduce expenses and seek options for maximizing shareholder returns under tough stock market conditions. However, CureVac and Supernus are among firms recently able to access new cash – $250m and $150m, respectively.

Finance Watch Public Company
• Source: Alamy

Strong clinical trial readouts can lead to surging stock prices and big follow-on public offerings (FOPOs), and in a less rocky market failed trial readouts mean that a biopharma company’s stock price may dip and a FOPO is not imminent. In the current volatile environment for publicly traded firms, failed studies are leading to significant cost cuts, massive layoffs and searches for strategic alternatives that may ultimately lead to dissolution of drug developers.

Aileron Therapeutics, Inc, Talaris Therapeutics, Inc. and Frequency Therapeutics Inc. are the latest companies to simultaneously disclose...

More from Financing

More from Business

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.